Today again something at $BNTX (-3,55%) today. The position will soon be full and my savings plan stopped.

$BNTX (-3,55%) has taken quite a beating in pre-market trading today. R.F. Kennedy and Peter Marks (FDA) have parted ways following differences of opinion on the subject of vaccinations. The vaccine values such as $BNTX (-3,55%) and $MRNA (-1,33%) have suffered. For me, this is a good opportunity to add to my BionTech position right after the US IPO - I am speculating on a breakthrough in the oncology pipeline in 2026. Biontech is one of my long term swings.

In addition to Biontech, I also added to my $RDC (-2,11%) Shopapotheke position again today.

Biontech $BNTX (-3,55%) has high hopes for its new drug candidate BNT327, which is being developed for the treatment of advanced cancer. This innovative approach aims to combat the tumor-related effects that weaken the body's own immune system. The acquisition of the Chinese company Biotheus secured Biontech the worldwide rights to this promising drug. But while the future looks promising, the Mainz-based company is facing a significant net loss of around 700 million euros in 2024. This continues the decline that began with the declining business around the Covid-19 vaccine. In 2022, Biontech was still able to record a profit of around 9.4 billion euros, but in 2023 this fell dramatically to only around 930 million euros. This is a clear indication that the company is in a transition phase and needs to develop new strategies to get back on the road to success.

In Germany, Volkswagen $VOW (-3,61%) is providing positive news for its employees: they can look forward to uncapped bonuses this year! Despite an ongoing austerity program and an agreement with IG Metall, which temporarily suspends profit sharing from 2026, the bonus for 2024 remains unaffected. Head of the Works Council Daniela Cavallo announced at the last works meeting that the bonus will continue to be paid in full. However, the exact amount of the bonus is still unclear, as it depends on the previous year's profit, which is to be published on March 11. Volkswagen has revised its profit forecast for 2024 downwards several times in recent months and now expects an operating profit of 18 billion euros. Despite the uncertainties and challenges, the company remains committed not only to supporting its employees, but also to keeping their motivation high.

Sources:

https://www.spiegel.de/wirtschaft/biontech-teure-entwicklung-von-krebsmedikamenten-fuehrt-zu-stellenabbau-a-23a1a698-7b5c-465d-bd3f-01032ea3288d

https://www.spiegel.de/wirtschaft/volkswagen-vw-mitarbeiter-duerfen-mit-praemien-in-voller-hoehe-rechnen-a-51abf27a-b728-4a48-8cc1-7c4c04c2ffd4

I bought the shares as a bet when the market was so expensive that I couldn't find anything more attractive. now there are some shares from my portfolio and also on the watchlist that I have more hope for in the long term, so I'm switching to other stocks when the market has calmed down a bit📈

Hello everyone,

My name is Antonio, I'm almost 27 years old and I'm from Bremen. I currently work as a train manager at Deutsche Bahn. Anyone who knows the job knows that chaos is almost guaranteed here. If a train is on time, everyone wonders what's going wrong. Delays, strikes, unforeseen events - you get used to the fact that nothing goes as expected. And that's exactly how I felt on the stock market: constantly chasing hypes, always on the lookout for quick profits, and in the end I never knew whether the train was still on the right track. I experienced just as much chaos on the markets as I did in my day-to-day work - but fortunately I've learned from it and am now looking for a fresh start where everything is a bit more orderly and predictable.

I've made a lot of mistakes on the stock market in the past. And not too few - unfortunately. Like many of you, I had the idea that the stock market would make me a quick buck. I let myself be led by hypes, trends and the desire for immediate results. I wasn't interested in investing for the long term or building a solid foundation for the future, I was only ever interested in making a quick profit. Leveraged products, knock-out certificates - it was all there. It felt like a casino where the loss was usually the only "win". And so it came as it had to: I not only lost money, but also confidence in my own decisions and the markets.

But today, in 2025, I have realized that it is time for a fresh start. I have learned from my mistakes. It's been a long road and I've thought a lot about why I was so quick to go for the quick buck instead of investing patiently and focusing on long-term success. I learned the lessons I needed to become a better investor. Patience, diversification and a long-term perspective are now my principles. I want to create something tangible, not just a portfolio full of numbers, but also a solid, long-term strategy that will help me to continuously build my wealth.

My portfolio: A solid foundation

The portfolio I have now built up is a mix of different asset classes and asset classes. My aim is to diversify broadly and not miss out on potential growth opportunities, while spreading risk across different sectors and regions. Here is an overview of what my investment strategy looks like:

ETFs (€1000/month)

I have deliberately opted for a broad diversification and invested in different geographical regions and markets. This diversification should ensure that my capital benefits from the markets that have the greatest potential in the coming decades.

- IE00BMTX1Y45 ( $I500) (-5,3%)

- LU0908500753 ( $MEUD (-5,66%) )

- IE00BYXVGY31 ( $FUSA (-4,98%) )

- IE00BD1F4M44 ( $IUVF (-5,82%) )

- IE00BKM4GZ66 ( $EIMI (-4,57%) )

- LU1681041973 ( $CD9 (-5,43%) )

- LU0486851024 ( $D5BL (-6,47%) )

- IE00BYQCZN58 ( $DXJZ (-4,63%) )

- IE00BF4RFH31 ( $WSML (-4,27%) )

- IE00BG0SKF03 ( $5MVL (-4,84%) )

- IE00B652H904 ( $SEDY (-3,96%) )

- LU2089238385 ( $PRAJ (-3,5%) )

- DE000A0H0744 ( $EXXW (-5,46%) )

- IE00BFXR5W90 ( $LGAG (-6,75%) )

- LU0779800910 ( $XCHA (-3,45%) )

- HANetf Future of Defense UCITS ETF ($ASWC (-8,84%) )

So many ETFs? Does he still have all his wits about him?

Some people will think exactly that when they look at my ETF list. And yes, I admit that the portfolio is pretty broadly based - perhaps too broad for some. But that's exactly my goal. I don't want to catch the one sector or the one region that is going through the roof. I want to have everything! If a market explodes somewhere in the world, then I want to be there. Be it through large caps, small caps, growth, value, technology or emerging markets, my approach is not to miss out on potential opportunities and at the same time not to put all my eggs in one basket. Some call it overdiversification, I call it my personal "all-world approach"

The idea behind the selection of these ETFs is that I want to focus on global markets and growth regions without missing out on important sectors such as technology, healthcare and energy. The USA (with over 55% of my portfolio) remains the central component due to its economic importance and innovative strength. At the same time, I am also focusing on Europe, Asia, China and emerging markets, which are increasingly among the growth markets of the future. Small caps also play a key role for me, as they often have the potential to grow faster and offer opportunities that are often overlooked by the large institutions.

Cryptocurrencies (€100/month in Bitcoin ( $BTC (+0,54%) ) €50/month in Ethereum ($ETH) (+1,03%)

I also invest in Bitcoin and Ethereum as I am convinced of the future of these digital currencies. Even if the volatility is high, I see the long-term potential of these technologies. For me, it is an opportunity to participate in the development of a new financial world.

Gold (50 €/month EUWAX Gold ($DE000EWG0LD1 (-0,32%) )

In uncertain times, I have realized how important it is to have conservative assets such as gold. The last few years of inflation and economic fluctuations have made me realize that gold can have a stabilizing effect, especially in times of crisis.

Individual stocks - My dividend strategy

I have also selected a few individual stocks that should not only offer me security, but also regular income through dividends. The reason for this is simple: I need something tangible, something visible. It's not just the pleasure of seeing the portfolio grow, but also the dividend that gives me the feeling of actively participating in the companies and benefiting from their success.

- 3M Co ($MMM (-8,14%) )

- Allianz ($ALV (-8,43%) )

- BioNTech ($BNTX (-3,55%) )

- Booking Holdings( $BKNG (-2,79%) )

- Coca-Cola ($KO (-3,58%) )

- LVMH ($MC (-4,14%) )

- MSCI Inc ($MSCI (-6,26%) )

- NextEra Energy($NEE (-5,91%) )

- Philip Morris ($PM (-5,99%) )

- Realty Income($O (-2,42%) )

BioNTech in particular, as a company that has promising potential not only during the pandemic but also beyond, is a long-term winner for me. Likewise NextEra Energy, which plays a key role in the renewable energy sector, and Booking Holdings, which should benefit from the global tourism trend. These companies not only pay dividends, but also show that you can benefit from a company's success with a long-term perspective.

Pension fund

I also invest in the DEVK pension fund (DE000A2PT1X3) through my employer $DE000A2PT1X3 . This fund is particularly important to me because of the generous contributions made by my employer and the solid returns. Even though the costs are somewhat higher, I see it as a long-term addition to my strategy.

Why this portfolio?

I built my portfolio this way because I believe in the potential of long-term global diversification. Rather than chasing short-term gains, I am looking for continuous value growth over many years. I want to support the right companies, benefit from promising markets and at the same time have a regular source of income through dividends.

I am no longer interested in making a quick buck. I have learned that true success in wealth accumulation lies in patience. And that's what it's all about: I want to create a solid foundation for the future - for myself, for my pension and perhaps for a house in a few years' time.

What do you think?

I'm really looking forward to hearing from you. What do you think of my strategy? Do you see any areas where I could diversify even more? Are there any asset classes or ETFs missing from my portfolio that would make sense for me? I am very keen to hear your opinions and advice.

Thank you for taking the time to read my story and strategy! I look forward to your feedback.

Best regards,

Antonio

The Mainz-based company Biontech $BNTX (-3,55%) is currently testing several active substances in phase 2 trials - but none have yet reached the lengthy phase 3 required for approval.

US competitor Moderna $MRNA (-1,33%) claims to have an active substance - mRNA-4157 - in two phase 3 trials: as an add-on therapy against melanoma and against a certain form of lung cancer, non-small cell lung cancer (NSCLC).

The Moderna preparation mRNA-4157 (V940) could in turn be approved in the foreseeable future for the treatment of melanoma.

The active ingredient is currently being tested in two phase 3 trials - against a form of lung cancer and against high-risk melanoma. In fact, the US Food and Drug Administration nach Angaben von Moderna und Merck has announced an accelerated approval process for the drug in combination with the immune checkpoint inhibitor pembrolizumab for melanoma therapy.

https://www.n-tv.de/wissen/Krebs-koennte-mit-mRNA-Praeparaten-besiegt-werden-article25509772.html

Hello everyone,

What do you think of the Biontech share at the moment, many difficult events are hitting the German company. Do you think it would make sense to hold on or would it be better to go out with a small profit? Unfortunately, I am very confused about the whole situation.

Here is a small excerpt from an article.

( https://www.boerse-global.de/biontech-aktie-die-wissen-nichts/295203 )

Thank you in advance. 😁

#biontech
$BNTX (-3,55%)

$BNTX (-3,55%) Could BioNTech become one of the top picks for 2025?

If the results of the current studies are confirmed, BioNTech could launch the first cancer therapies on the market in 2026. You can imagine what that means. That would give the share a strong boost🚀

Even though the share price has already moved quite a bit away from the lows in the summer, it is still an interesting level!

Daily chart:

Weekly chart:

BioNTech exhibits "OUTSTANDING" financial health, supported by strong cash flow metrics.

According to BMO Capital, the safety profile of BNT324 is in line with other ADCs currently available on the market. BioNTechs
strong
financial
positionwith more cash than debt and a healthy liquidity ratio of 7.33, provides robust support for its drug development initiatives. In addition, they highlighted that the drug showed promising early efficacy results, particularly in patients with small cell lung cancer (SCLC).

BioNTech's continued Outperform rating reflects confidence in the drug's potential and its alignment with the company's development goals.

I have BioNTech in my portfolio and it is also one of the few individual stocks in my children's portfolios - the time factor plays into their hands anyway 😎🏦

Source: https://de.investing.com/news/analyst-ratings/bmo-halt-an-outperformbewertung-fur-biontechaktien-fest-93CH-2796832

For which share would you like to prepare a short analysis with an outlook next? Currently interesting are certainly $NOVO B (-6,66%) , $ASML (-2,09%) , $MSTR (+4,34%) or $BNTX (-3,55%)